Earnings Call · Q4 FY2024·2025-02-26

Q4 24EPS +100.00%*·Rev n/aQ3 24EPS +42.86%·Rev n/aQ2 24EPS +11.11%·Rev n/aQ1 24EPS +66.67%·Rev n/a⚠ consensus missing

ACADIA PHARMACEUTICALS INC ACAD

Al Kildani — Senior Vice President of Investor Relations and Corporate Communications

Catherine Owen Adams — Chief Executive Officer

Tom Garner — Chief Commercial Officer

Elizabeth Thompson — Head of Research and Development

Mark Schneyer — Chief Financial Officer

+1.8%1d on move date+3.4% vs SPY3d−4.4%5d−4.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ACAD calls or request research access.

More ACAD calls Browse calls Request research access